| Market Capitalization (Millions $) |
4,468 |
| Shares
Outstanding (Millions) |
308 |
| Employees |
511 |
| Revenues (TTM) (Millions $) |
633 |
| Net Income (TTM) (Millions $) |
-27 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Amicus Therapeutics is an American biopharmaceutical company founded in 2002, based in Cranbury, New Jersey. The company is focused on developing and commercializing new treatments for rare and orphan diseases, including lysosomal storage disorders (LSDs) of genetic origin.
The company's mission is to unlock the potential of genetic medicine to improve the lives of people affected by rare and devastating diseases. They are dedicated to conducting rigorous research to uncover new therapeutic approaches to these diseases, and to bringing safe and effective treatments to market.
Amicus Therapeutics has a diverse portfolio of small molecule and gene therapy drug candidates that are designed to address various LSDs. They currently have three approved products: Galafold, a small molecule medication for the treatment of Fabry disease, which is a genetic disorder that leads to the accumulation of a type of fat in the body called globotriaosylceramide (Gb3); Migalastat, an oral medication that is used in combination with enzyme replacement therapy (ERT) for patients with Fabry disease; and Jivi, a recombinant factor VIII therapy used for the treatment of hemophilia A.
In addition to their approved products, Amicus Therapeutics also has several promising drug candidates in development, such as AT-GAA, a gene therapy for Pompe disease that is currently in Phase 3 clinical trials.
Amicus Therapeutics has a strong commitment to patient advocacy and engagement, working closely with patient organizations and advocacy groups to ensure that the needs and concerns of patients are taken into account in their research and development efforts.
Overall, Amicus Therapeutics is a leading company in the field of rare and orphan diseases, with a strong focus on developing innovative and effective treatments to improve the lives of patients affected by these devastating conditions.
Company Address: 47 Hulfish Street Princeton 8542 NJ
Company Phone Number: 662-2000 Stock Exchange / Ticker: NASDAQ FOLD
|
0.000%
2.88% 
82.06 %